Just like the two different questions, there are two conversations going on right now in Philadelphia about supervised-injection sites. One is a macro conversation about whether these sites are a legitimate and efficacious tool that should be considered as part of our response to the overdose crisis. The evidence to support a site in Philadelphia is overwhelming. The much harder conversation is the micro one about where and how it would work: Where should a site be? How many sites? What should be the model of operation? And who should take responsibility for the site? Philadelphia is far from pinpointing those critical details, and that is a conversation we must engage in together.